Accès à distance ? S'identifier sur le proxy UCLouvain
Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation:
Primary tabs
Document type | Article de périodique (Journal article) |
---|---|
Access type | Accès restreint |
Publication date | 2012 |
Language | Anglais |
Journal information | "Journal of Clinical Oncology" - Vol. 30, no.20, p. 2475-82 (2012) |
Peer reviewed | yes |
Publisher | American Society of Clinical Oncology ((United States) Alexandria) |
issn | 0732-183X |
e-issn | 1527-7755 |
Publication status | Publié |
Affiliations |
UCL
- SSS/IREC/MONT - Pôle Mont Godinne UCL - (MGD) Service d'hématologie |
MESH Subject | Adult ; Male ; Middle Aged ; Multiple Myeloma ; Pyrazines ; Recurrence ; Stem Cell Transplantation ; Thalidomide ; Transplantation, Autologous ; Treatment Outcome ; Aged ; Antineoplastic Combined Chemotherapy Protocols ; Boronic Acids ; Dexamethasone ; Disease-Free Survival ; Drug Administration Schedule ; Female ; Humans |
Links |
Bibliographic reference | Garderet, Laurent ; Iacobelli, Simona ; Moreau, Philippe ; Dib, Mamoun ; Lafon, Ingrid ; et. al. Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: . In: Journal of Clinical Oncology, Vol. 30, no.20, p. 2475-82 (2012) |
---|---|
Permanent URL | http://hdl.handle.net/2078.1/123710 |